Reckitt Sees End Of Mucinex Exclusivity Despite Delay Attempts
This article was originally published in The Tan Sheet
Executive Summary
Reckitt Benckiser expects to lose OTC exclusivity for its Mucinex cough cold line as early as 2011 even as it attempts to delay private label competition